Top Markets
Coin of the day
Newron Pharmaceuticals S.p.A. Newron Pharmaceuticals S.p.A.

Newron Pharmaceuticals S.p.A.

NP5
Clasificación en acciones #15973
Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in... Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in Bresso, Milano, with a dedicated team of 24 full-time employees. The company's core mission is the discovery and advancement of innovative pharmaceutical products, particularly focusing on new therapies for Central Nervous System (CNS) disorders and pain management. Among its leading candidates, safinamide is currently undergoing Phase III clinical trials for the treatment of Parkinson's disease. Additionally, ralfinamide is being developed as a potential therapy for neuropathic pain. The firm's pipeline further includes a range of projects at various preclinical and clinical development stages, such as HF0220 for neuroprotection, NW-3509 for schizophrenia, and pruvanserin and sarizotan for other CNS conditions.
Precio por acción
$15.42
Capitalización bursátil
$320.83M
Cambio (1 día)
-1.52%
Cambio (1 año)
40.67%
País
IT
Comercio Newron Pharmaceuticals S.p.A. (NP5)

Categoría

Historial de rendimiento por dividendo de Newron Pharmaceuticals S.p.A. (NP5)
Rendimiento por dividendo (TTM) de Newron Pharmaceuticals S.p.A. (símbolo bursátil: NP5) al 2026: 0
Rendimiento promedio por dividendo de los últimos 5 años: 0.00%
Historial de rendimiento por dividendo de Newron Pharmaceuticals S.p.A. (NP5) desde 2026 hasta 2026
Rendimiento por dividendo al final de cada año (TTM)
Año Rendimiento por dividendo Cambiar
Not enough data for the provided dates.
Rendimientos por dividendo (TTM) de empresas similares o competidoras
Empresa Rendimiento por dividendo País
0.00%
US
0.00%
NL
0.00%
US
2.48%
AU
0.00%
CH